GeneNovate Final Event & Investors’ Day 2025

Berlin, June 2025 – The GeneNovate Final Event and the subsequent Investors’ Day marked an important milestone for Germany’s national innovation initiative in gene and cell therapy.

On June 26, 2025, more than 200 participants—including startups, researchers, policymakers, and investors—gathered at the Akademie der Künste in Berlin to celebrate the conclusion of the program’s recent cycle. A total of 23 teams presented their business ideas, with four projects from Berlin, Hannover, Heidelberg, and Dresden/Leipzig selected as winners. These teams will now receive targeted coaching and the opportunity to present at the 2026 Investors’ Day. The event highlighted the strong regional participation from six innovation hubs across Germany, fostering exchange and collaboration between science, business, and policy.

The following day, June 27, 2025, the GeneNovate Investors’ Day provided a dedicated platform for dialogue between entrepreneurs and the investment community. The program combined high-level keynote addresses and panel discussions with structured networking opportunities. Topics ranged from financing and translation to the future of patient-centered therapies. Representatives from academia, industry, regulatory bodies, and politics contributed to the exchange, underlining the relevance of this growing field for Germany’s healthcare and innovation landscape.

Together, the Final Event and Investors’ Day demonstrated the momentum of the GeneNovate initiative, the strength of Germany’s research and entrepreneurial ecosystem, and the commitment of diverse stakeholders to advancing gene and cell therapy innovation.